Chlamydia pneumoniae induces macrophage-derived foam cell formation via PPAR α and PPAR γ-dependent pathways

Cell Biology International

Volumn 33, Issue 3, 2009, Pages 301-308

  Mei, Chun li ^a   He, Ping ^a   Cheng, Bei ^a   Liu, Wei ^a   Wang, Yan fu ^a   Wan, Jing jing ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Atherosclerosis; Chlamydia pneumoniae; Foam cells; Peroxisome proliferator activated receptor ; Peroxisome proliferator activated receptor

Indexed keywords

CHOLESTEROL; CHOLESTEROL ESTER; FENOFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

ARTICLE; ATHEROGENESIS; CHLAMYDIAL PNEUMONIA; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; FOAM CELL; HUMAN; HUMAN CELL; LIPID METABOLISM; MACROPHAGE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

CHLAMYDOPHILA PNEUMONIAE; CHOLESTEROL ESTERS; DOWN-REGULATION; FOAM CELLS; HUMANS; HYPOGLYCEMIC AGENTS; LIPOPROTEINS, LDL; MACROPHAGES; PPAR ALPHA; PPAR GAMMA; PROCETOFEN; THIAZOLIDINEDIONES;

CHLAMYDOPHILA PNEUMONIAE;

EID: 61349195137     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellbi.2008.12.002     Document Type: Article

References (38)

1. Babaev V.R., Ishiguro H., Ding L., Yancey P.G., Dove D.E., Kovacs W.J., et al. Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerotic lesion in low-density lipoprotein receptor-deficient mice. Circulation 116 (2007) 1404-1412
2. Barbier O., Torra I.P., Duguay Y., Blanquart C., Fruchart J.C., Glineur C., et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 22 (2002) 717-726
3. Belland R.J., Quellette S.P., Gieffers J., and Byrne G.I. Chlamydia pneumoniae and atherosclerosis. Cell Microbiol 6 (2004) 117-127
4. Burns K.A., and Vanden Heuvel J.P. Modulation of PPAR activity via phosphorylation. Biochim Biophys Acta 1771 (2007) 952-960
5. Campbell L.A., Rosenfeld M., and Kuo C.C. The role of Chlamydia pneumoniae in atherosclerosis - recent evidence from animal models. Trends Microbiol 8 (2000) 255-257
6. Castrillo A., and Tontonoz P. Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu Rev Cell Dev Biol 20 (2004) 455-480
7. Chawla A., Boisvert W.A., Lee C.H., Laffitte B.A., Barak Y., Joseph S.B., et al. A PPAR γ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7 (2001) 161-171
8. Chinetti G., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 49 (2000) 497-505
9. De Villiers W.J., and Smart E.J. Macrophage scavenger receptors and foam cell formation. J Leukoc Biol 66 (1999) 740-746
10. Gamble W., Vaughan M., Kruth H.S., and Avigan J. Procedure for determination of free and total cholesterol in micro- or nanogram amounts suitable for studies with cultured cells. J Lipid Res 19 (1978) 1068-1070
11. Gardner O.S., Dewar B.J., and Graves L.M. Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling. Mol Pharmacol 68 (2005) 933-941
12. Gaydos C.A., Summersgill J.T., Sahney N.N., Ramirez J.A., and Quinn T.C. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun 64 (1996) 1614-1620
13. Glass C.K., and Witztum J.L. Atherosclerosis. The road ahead. Cell 104 (2001) 503-516
14. Goldstein J., and Brown M. The low-density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem 46 (1997) 897-930
15. Huang B., Dong Y., Mai W., and Li Y. Effect of Chlamydia pneumoniae infection and hyperlipidaemia on the expression of PPAR γ, P50 and c-Fos in aortic endothelial cells in C57BL/6J mice. Acta Cardiol 60 (2005) 43-49
16. Kalayoglu M.V., and Byrne G.I. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis 177 (1998) 725-729
17. Kalayoglu M.V., Hoerneman B., LaVerda D., Morrison S.G., Morrison R., and Byrne G.I. Cellular oxidization of low density lipoprotein by Chlamydia pneumoniae. J Infect Dis 180 (1999) 780-790
18. Kim Y.H., Choi S.Y., Suh J.H., Kim T.K., Seung K.B., Wang Y.P., et al. The effect of Chlamydia pneumoniae on the expression of peroxisome proliferator-activated receptor-γ in vascular smooth muscle cells. Yonsei Med J 49 (2008) 230-236
19. 2-terminal kinase. Microbes Infect 9 (2007) 1410-1414
20. Kleinveld H.A., Hak-Lemmers H.L., Stalenhoef A.F., and Demacker P.N. Improved measurements of low-density-lipoprotein susceptibility to copper-induced oxidation: application of a short procedure for isolating low-density-lipoprotein. Clin Chem 38 (1992) 2066-2072
21. Krull M., Kramp J., Petrov T., Klucken A.C., Hocke A.C., and Walter C. Differences in cell activation by Chlamydophila pneumoniae and Chlamydia trachomatis infection in human endothelial cells. Infect Immun 72 (2004) 6615-6621
22. Kuo C.C., Shor A., Campbell L.A., Fukushi H., Patton D.L., and Grayston J.T. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 167 (1993) 841-849
23. Kuvin J.T., and Kimmelstiel C.D. Infectious causes of atherosclerosis. Am Heart J 137 (1999) 216-226
24. Lee C.H., and Evans R.M. Peroxisome proliferator-activated receptor γ in macrophage lipid homeostasis. Trends Endocrinol Metab 13 (2002) 331-335
25. Lee C.H., Olsom P., and Evans R.M. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144 (2003) 2201-2207
26. Li A., Brown K., Silvestre M., Wilson T., Palinski W., and Glass C. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106 (2000) 523-531
27. Liu C., and Waters D.D. Chlamydia pneumoniae and atherosclerosis: from Koch postulates to clinical trials. Prog Cardiovasc Dis 47 (2005) 230-239
28. Lusis A.J. Atherosclerosis. Nature 407 (2000) 233-241
29. Moazed T.C., Campbell L.A., Rosenfeld M.E., Grayston J.T., and Kuo C.C. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. J Infect Dis 180 (1999) 238-241
30. Moore K.J., Rosen E.D., Fitzgerald M.L., Randow F., Andersson L.P., Altshulter D., et al. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med 7 (2001) 41-47
31. Ngeh J., Anand V., and Gupta S. Chlamydia pneumoniae and atherosclerosis - what we know and what we don't. Clin Microbiol Infect 8 (2002) 2-13
32. Rinninger F., Brundert M., Jackle S., Kaiser T., and Greten H. Selective uptake of low density lipoprotein associated cholesterol esters by human fibroblasts, human HepG2 hepatoma cells and J744 macrophages in culture. Biochim Biophys Acta 1255 (1995) 141-153
33. Roblin P.M., Dumornay W., and Hammerschlag M.R. Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae. J Clin Microbiol 30 (1992) 1968-1971
34. Saikku P., Leinonen M., Mattila K., Ekman M.R., Nieminen M.S., Makela P.H., et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 2 (1988) 983-986
35. Schaffner T., Taylor K., Bartucci E.J., Fischer-Dzoga K., Beeson J.H., Glagov S., et al. Arterial foam cells with distinctive immunomorphologic and histochemical features of macrophages. Am J Pathol 100 (1980) 57-80
36. Steinberg D. Oxidative modification of LDL and atherogenesis. Circulation 95 (1997) 1062-1071
37. Tabas I. Consequence of cellular cholesterol accumulation: basic concepts and physiological implications. J Clin Invest 110 (2002) 905-911
38. Zandbergen F., and Plutzky J. PPAR α in atherosclerosis and inflammation. Biochim Biophys Acta 1771 (2007) 972-982